NRx PharmaceuticalsNASDAQ: NRXPW

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

NRx Pharmaceuticals is in the Healthcare sector

NRx Pharmaceuticals is in the Biotechnology industry

NRx Pharmaceuticals is headquartered in United States

NRx Pharmaceuticals initial public offering (IPO) was on 01 December 2017

https://www.nrxpharma.com

No, NRx Pharmaceuticals is not included in the S&P 500 index

No, NRx Pharmaceuticals is not included in the NASDAQ 100 index

No, NRx Pharmaceuticals is not included in the Dow Jones index

No data